Tempus announced its acquisition of Ambry Genetics at closing in November and the deal closed earlier this month.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics ...

In addition, the company just acquired Ambry Genetics for hereditary cancer tests helping Tempus AI expand into other areas such as rare disorder, pediatrics and cardiology. Tempus AI recently ...

Everyone has their own rules for Super Bowl squares, but here at For The Win we’ve put together an easy-to-read — and printable! — template for you and your party to enjoy. Gambling involves ...

Investing.com -- TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech company completed its $600 million acquisition of Ambry ...

CROWN POINT — Prosecutors dismissed murder charges Thursday against a Gary man accused of tracking down the man who allegedly stole his brother's car and killing him, according to Lake Criminal ...

Tempus has been growing through acquisitions too. It is acquiring Ambry Genetics at $600 million this year. $375 million will be in cash and $225 million in equity. The company is still ...

KUALA LUMPUR: Asean has the potential to become a 'middle power', which is a power that can play an important role in dealing with tensions between great powers, not with the aim of war, but as a ...